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Variations introduced to medicinal product documentation must not affect the quality, effi cacy, and safety 
of the product. Croatian Medicinal Products Act and accompanying ordinances are largely aligned with the 
EU regulations. The EU has now tried to simplify the issue of variations with a new Regulation, creating 
differences in the defi nition of and approach to resolving certain types of variations between Croatia and 
the EU. These differences could hinder the approval procedure for variations in Croatia, particularly for 
medicines already approved in the EU. Amending the Croatian Ordinance on medicines already authorised 
in the EU would be one way of maintaining the effi ciency of the Croatian regulatory system.
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Marketing authorisation of a medicinal product is 
granted based on the product documentation, which 
must contain all data and documents confi rming its 
quality, effi cacy, and safety. In the Republic of Croatia, 
the content of this documentation is determined by the 
Medicinal Products Act and subordinate legislation. 
Pursuant to the Act, the Minister responsible for health 
and social welfare issues ordinances which describe 
procedures set by the law with greater clarity and in 
more detail. Since 1997, relevant legislation has been 
amended several times in the EU and Croatia, in line 
with new fi ndings pertaining to medicinal products, 
public health, and regulations. Most of the medicinal 
products from the EU Member States are available 
in Croatia alongside our own medicinal products. 
As Croatia has applied for the EU membership, its 
legislation concerning medicinal products has largely 
been aligned with that of the European Union.
Documentation for medicinal products is subject 
to change. Handling of variations requires signifi cant 
administrative and regulatory efforts which involve both 
competent authorities and industry (1-3). Variations 
have to be implemented in such a way not to affect the 
quality, effi cacy, and safety of the medicinal product.
According to the 2007 Medicinal Products Act 
still in force, marketing authorisation holder for 
a medicinal product is required to keep up with 
scientifi c and technical advancements and to introduce 
appropriate variations to assure that the manufacture 
and quality control of the medicinal product are in 
line with generally accepted scientific principles 
(4, 5). Variations to medicinal product data can 
result from amendments to regulations, operations 
of the manufacturer or marketing authorisation 
holder, market demand, or other economic reasons. 
Furthermore, certain variations may result from 
regulatory action initiated by competent authorities or 
marketing authorisation holder, in line with the new 
safety information that could affect the risk/benefi t 
ratio of the product.
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The objective of this article is to give a chronological 
overview of provisions concerning variations in 
documentation on medicinal products for human use 
in the Croatian legislation from 1997 to 2009. It also 
brings an overview of the most important provisions of 
the new Commission Regulation (EC) No. 1234/2008 
on variations and a comparison with current Croatian 
regulations.
OVERVIEW OF THE PROVISIONS 
ON VARIATIONS IN THE CROATIAN 
LEGISLATION FROM 1997 TO 2009
The Croatian legislation classifi es variations into 
several categories, depending on their impact on the 
quality, effi cacy, and safety of a medicinal product 
and related risks. Variations are primarily regarded as 
minor (types IA and IB) or major (type II).
The procedure, conditions, and documentation 
for granting, renewal, revocation, and transfer of 
marketing authorisation for a medicinal product in 
Croatia, and for acceptance and approval of variations 
to the authorisation and documentation on a medicinal 
product are defi ned by the 2007 and 2009 Medicinal 
Products Act and two ordinances (4-7).
According to these regulations, marketing 
authorisation holder is required to submit an 
application to the Agency for Medicinal Products 
and Medical Devices for approval of variations of 
the marketing authorisation or medicinal product 
documentation before the variations are applied. A 
separate application for each variation is required, 
except in cases of consequential variations (6).
The fi rst Croatian Act on Medicinal Products and 
Medical Devices from 1997 and its amendment from 
2001 did not contain any provisions on variations 
of the marketing authorisation or medicinal product 
documentation (8, 9).
The Ordinance on the procedure and method 
for granting marketing authorisations for medicinal 
products came into effect in 1998. In addition to 
defi ning the procedure and documentation required 
for issuing marketing authorisation for medicinal 
products, it also laid down provisions on variations 
to medicinal product documentation. It became 
mandatory for marketing authorisation holder to 
submit an application to the minister of health for each 
variation in accordance with authorisation granted 
(10). Until the establishment of the Agency in 2003, 
marketing authorisations were granted by the Ministry 
of Health of the Republic of Croatia.
The Ordinance dist inguished two types 
of variations, minor and major, and listed the 
documentation to be submitted with the application 
for approval of the variation (10). It listed all minor 
variations and conditions that each variation had to 
meet to be considered a minor variation. However, 
documentation to be submitted with the application for 
approval of the variation was not clearly defi ned. Major 
variations were considered all those not included in the 
group of minor variations. These were further divided 
into those requiring a new application for marketing 
authorisation, which were clearly listed, and those 
requiring an application for approval of variations, 
which were not clearly listed (10). The Ordinance 
also defi ned the content of the documentation to be 
submitted for switching from prescription to over-the-
counter issuance of a product.
The 2003 Act on Medicinal Products and Medical 
Devices and its 2004 amendment (11, 12) brought 
signifi cant changes to the regulation of medicinal 
products for human use. The Act established the 
Agency for Medicinal Products and Medical Devices, 
modelled after similar agencies of the EU Member 
States, to carry out the complete procedure of issuing 
marketing authorisation. The provisions of the Act 
were largely aligned with the EU Directives (18-
20).
Unlike the earlier Act, this Act contained provisions 
important for variations and defi ned the application 
procedure and time for approval of variations to 
the medicinal product documentation or marketing 
authorisation (Table 1). The Act foresaw a new 
ordinance that would define the procedure and 
content of the documentation for issuing, renewing or 
changing authorisations, but the new ordinance was 
not passed and a series of discrepancies arose between 
the provisions of the new Act and the old Ordinance 
which was in force at the time. This made variation 
approval diffi cult.
This situation partly improved with the 2004 
Ordinance on special conditions for placing medicinal 
products authorised in the Member States of the 
European Union on the market of the Republic of 
Croatia (13). However, this Ordinance laid down 
provisions applicable to medicinal products approved 
in the EU Member States pursuant to the centralised 
procedure, mutual recognition procedure, and national 
procedures of the United Kingdom, Ireland, Sweden, 
Denmark, and the Netherlands, but did not apply to 
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medicinal products of domestic manufacturers and 
those from non-EU countries (13). Its objective was 
to simplify and speed up assessment and approval 
of medicinal products previously assessed and 
approved by the competent authorities in the EU 
Member States. Accordingly, the applicant was 
required to demonstrate previous approval in the 
EU with appropriate documentation. The Ordinance 
clearly defi ned conditions and documents needed 
for authorising variations in these circumstances. It 
stipulated that documentation submitted to competent 
authorities in Croatia was to be identical to the one 
submitted in the EU and that the authorisation holder 
was to report all variations to both the Agency and a 
competent authority in the EU Member State (13).
The new, 2008 Ordinance (7) has established 
special conditions for marketing medicinal products 
in Croatia that have been approved in the EU Member 
States through a centralised procedure (the European 
Medicines Agency is responsible for this procedure 
which results in a single marketing authorisation valid 
across the EU), mutual recognition procedure (after 
one EU Member State has authorised a medicine in 
accordance with its national procedure, other EU 
countries may recognise the validity of the original, 
national marketing authorisation) or a decentralised 
procedure (a medicine is authorised in several EU 
countries at the same time). The last two procedures are 
used where the centralised procedure is not mandatory. 
This Ordinance more clearly defi nes variations and is 
Table 1 Comparison of legal provisions from 1997 to 2009
Considered 
parameter




Act on Medicinal 
Products and Medical 
Devices 
(11, 12)
Act on Medicinal Products
(4, 5)
Assessment of 
validity of the 
application
No specifi c provisions 
on variations
30 days Agency requests amendment of incomplete 




90 days 90 days from receipt of valid application
Types of variations Not classifi ed Not classifi ed
New: contains provisions on the transfer of 
authorisation to another legal person in Croatia, and 
provisions concerning extraordinary safety measures 
that could result in variations to authorisation or 
documentation
Figure 1  Review of Croatian laws on medicinal products for human use from 1997 to 2009 relevant for variations to marketing 
authorisation or medicinal product documentation from 1997 to 2009
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the fi rst to distinguish minor (types IA and IB) and 
major (type II) variations, and variations due to urgent 
safety restrictions. However, the Ordinance does not 
provide a list of variations. It defi nes the time and 
documents needed for the application for approval 
of variations to be submitted to the Agency (Table 
2) and an application form for every pharmaceutical 
form, strength, or packaging (7).
The current 2007 Medicinal Products Act and its 
2009 amendment (4, 5) for the fi rst time in Croatia 
brings provisions related to medicinal products only 
and continues the alignment with the EU legislation. 
Provisions on variations are now more complete 
and precise. The Act also defines the transfer of 
authorisation to another legal person seated in 
Croatia and urgent safety restrictions that could 
lead to variations to the marketing authorisation or 
documentation (4, 5). Table 1 outlines the differences 
in respect to earlier acts.
The  approva l  p rocess  and  con ten t  o f 
the documentation submitted for changing the 
authorization are outlined in detail in the 2008 
Ordinance on the procedure and method for granting 
marketing authorizations for medicinal products (6). In 
comparison with the 1998 Ordinance, it more precisely 
defi nes the procedure, conditions, and documentation 
necessary for approval of variations to the marketing 
authorisation and documentation on a medicinal 
product. It distinguishes minor (IA and IB) and major 
(II) variations and consequential variations and defi nes 
procedures for certain pharmacovigilance variations 
(Table 2) (6).
The Ordinance gives a detailed list of minor 
variations (IA, IB), reporting conditions, and 
documentation to be submitted depending on the 
reported variation. Major variations (II) are defi ned as 
those that cannot be considered minor variations and 
as those not requiring initiation of a new marketing 
authorisation procedure, or those requiring initiation 
of a new marketing authorisation procedure (6).
The Ordinance defi nes a consequential variation 
as a variation ensuing from other variations that 
cannot be avoided. For example, a type IA variation 
may be a consequential variation of another type IA 
variation, a type IB variation may be a consequential 
variation of another type IB or IA variation, while 
other consequential variations are reported as part of 
type II variations (6).
Variations due to urgent safety measures are 
variations introduced on account of new information 
on the use of a medicinal product due to which urgent 
restrictions must be imposed on the authorised use 
of the medicinal product in the interest of public 
health protection. Such measures include narrower 
therapeutic range, changes in posology, restriction 
of use to a limited group of patients, extension of 
contraindications or precautionary measures.
Unlike the 1998 Ordinance, the 2008 Ordinance 
provides a special form for variations to be submitted 
with the application.
Provisions defi ning the deadlines for approval of 
the variations have also amended and depend on the 
type of variations (Table 2).
The Ordinance also defines variations to the 
summary of product characteristics, package leafl et, 
and labelling of the medicinal product that can 
exceptionally make part of authorisation renewal 
based on a conclusion in the enclosed Periodic 
Safety Update Report (PSUR), to align the name of a 
pharmaceutical form and ingredients with the Croatian 
pharmacopeia, and to align the format of the summary 
of product characteristics, package leafl et, and product 
labelling with the current Act and this Ordinance 
without affecting their content. Any other variation 
requires a separate application (6).
COMMISSION REGULATION NO 1234/2008 
OF 24 NOVEMBER 2008 CONCERNING THE 
EXAMINATION OF VARIATIONS TO THE 
TERMS OF MARKETING AUTHORISATIONS 
FOR MEDICINAL PRODUCTS FOR HUMAN 
USE AND VETERINARY MEDICINAL 
PRODUCTS
The Regulation of the European Commission 
concerning the examination of variations to the 
terms of marketing authorisations for medicinal 
products for human use and veterinary medicinal 
products was passed on 24 November 2008. It came 
into force on 1 January 2010 (14). This Regulation 
was preceded by Commission Regulations Nos. 
1084/2003 and 1085/2003 as, following detailed 
analysis, it was established that these presented a 
burden to both industry and regulatory authorities 
(15-17). These regulations defi ned procedures for 
approval of variations to marketing authorisations 
granted based on the centralised and decentralised 
procedures, but not for those based on purely national 
procedures which differ among the EU Member States 
and the majority of reported variations pertain to 
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Ordinance on special 
conditions for placing 
medicinal products 
authorised in the 
Member States of the 
European Union on the 
market of the Republic 
of Croatia (13)
Ordinance on special 
conditions for placing 
medicinal products 
authorised in the 
Member States of the 
European Union on the 
market of the Republic 
of Croatia (7)
Ordinance on the 
procedure and method 









prescription to over- 
the- counter issuance 
of a product
Provisions on variations 
approved in the EU
No mention of the types 
of variations
- Provisions on variations 
approved in the EU
- minor (IA and IB), 
- major (II), 
- variations due to 
extraordinary safety 
measures
- minor (IA, IB)
- major (II), and




-  due to extraordinary safety 
measures,
-  in time of submission of 
Periodic Safety Update 
Reports (PSURs), 
-  in the description of the 
pharmacovigilance system
-  in the risk management 
plan.
Provisions on switching from 
prescription to over- the- 














No deadline Deadline for marketing 
authorisation holder to 
complete the application: 
45 days from receipt 
of notifi cation from the 
Agency
Marketing authorisation 
holder submits a request to 
the Agency for approval of 
variations within 60 days 
of their approval in the EU
Deadline to complete 
application: 30 days 
(Approval of variations 
according to the 2007 Act: 
90 days)
Deadline for marketing 
authorisation holder 
complete application: 
30 days from receipt of 
notifi cation from the Agency
Approval:
Minor variations (IA, IB): 
30 days 
Major variations (II): 90 
days from receipt of valid 
application
Novelty: if the Agency does 
not inform the applicant of 
approval of the variation 
within 30 days of receipt of 
application reporting a minor 
variation (IA) not requiring 
an amendment of the 
marketing authorisation, it is 
automatically granted
these procedures (1). The lack of alignment between 
national procedures for resolving variations can 
hinder free movement of medicinal products between 
countries (1). Therefore, the objective of the new EC 
Regulation was to establish a simpler, clearer and 
more fl exible legislative framework for variations, 
aimed at reducing administrative burden, adopting 
ICH concepts, and aligning the procedures among 
the EU Member States, while also ensuring a uniform 
level of public human and animal health protection 
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notifi cation and 
documents within 
12 months of 
implementation 






informs the marketing 
authorisation holder and 
other relevant authorities 
within 30 days of the 
status of the variation 













to all relevant 
authorities
Competent authority of 
the reference member 
state confi rms validity 
of the notifi cation after 
consulting other member 
states
If no authorities disagree 
within 30 days, the 
notifi cation is accepted
Competent authority of the 
reference member state informs 
marketing authorisation holder 
and other relevant authorities of 
the member state of acceptance 
of the notifi cation
DCP/minor 
variations of 




informs the marketing 
authorisation holder and 
other relevant authorities 
of the rejection, citing 
reasons 
Marketing authorisation 
holder may submit an 
amended notifi cation to 
all relevant authorities 
within 30 days. The 
competent authority of 
the reference member 
state assesses it within 30 
days and delivers its fi nal 
opinion to the marketing 
authorisation holder and 
other relevant authorities
If the marketing authorisation 
holder does not amend the 
notifi cation as required, it shall 












to all relevant 
authorities
Competent authority 
acknowledges receipt of 
the valid application and 
informs the marketing 
authorisation holder and 
other relevant authorities 
of the start of the 
procedure
Competent authority of 
the reference member 
state issues an application 
assessment report 
and a decision on the 
application, and informs 
other relevant authorities 
within 60 days (may 
be reduced in urgent 
situations or extended to 
90 days for changes to 
therapeutic indications)
The competent authority of 
the reference member state 
may request supplementary 
information from the marketing 
authorisation holder, and 
inform other member states 
that the procedure is suspended 









authority of the 
reference member 
state within 30 
days
If no authorities 
disagree in this period, 
the decision on the 
application is adopted
If the decision is accepted 
by all relevant authorities, 
the reference authority 
informs the marketing 
authorisation holder and 
other authorities of the 
status of the variation and 
possible amendments to 
the decision on granting 
marketing authorisation 
If the variation represents a 
serious public health threat, the 
reference authority forwards the 
case to the coordination group 
for discussion
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(1, 17). This will be achieved, among other things, 
through provisions on worksharing procedure and 
through simplifi ed implementation of minor type IA 
variations. The categorisation of variations has also 
been amended; major variations with greater impact on 
the quality, effi cacy, and safety of a medicinal product 
are clearly defi ned, while variations not foreseen 
under the Regulation are considered minor type IB 
variations. The Regulation does not defi ne transfer of 
authorisations from one holder to another and is not 
applicable for variations to homeopathic or traditional 
herbal medicinal products approved pursuant to a 
simplifi ed registration procedure (14).
Minor type IA variations
Minor type IA variations are divided into those 
for which competent authority can be notifi ed at 
any time up to 12 months after implementation and 
those for which notifi cation is sent immediately after 
implementation. The notifi cation can take the form of 
a special notice or of an annual report containing a list 
of all implemented minor type IA variations. However, 
variations that require immediate notifi cation and 
all other variations requiring approval prior to 
implementation are not included in this report (14).
This should simplify approval of variations, reduce 
the number of applications, and give competent 
authorities more time to concentrate on variations 
that really affect the quality, safety, and effi cacy of 
medicinal products. 
Major type II variations
Major variations of type II are defi ned as those 
variations that are not extensions of marketing 
authorisations and which could have a signifi cant 
impact on the quality, efficacy, and safety of a 
medicinal product. These are listed in the Regulation 
(14).
Minor type IB variations (including article 
5 recommendations)
The Regulation defines and lists minor type 
IA variations, major type II variations, extensions 
of marketing authorisations, cases for grouping 
variations, and minor type IB variations that are not 
included under any of the given lists. (14).
Earlier Regulations clumped all unforeseen 
variations into the category of major variations and, 
for that reason, some seemingly simple variations 
were required to undergo a complicated procedure (1). 
The new Regulation requires that all variations whose 
classification is ambiguous should be considered 
minor type IB variations in the sense that this category 
applies by default (14). However, these variations 
are considered major if the marketing authorisation 
holder or a competent authority fi nds them to have a 
signifi cant impact on the quality, effi cacy, and safety 
of a medicinal product (14).
The Regulation allows marketing authorisation 
holders before they submit an application to directly 
request a recommendation of the variation classifi cation 
from European Medicines Agency (EMA) or from a 
relevant coordination group consisting of experts EU 
Member States authorities, who review any issues 
related to marketing authorisation in two or more 
Member States. The recommendation must be issued 
within 45 days of the request. Copies are delivered 
to the marketing authorisation holder, EMA, and 
the competent authorities of the EU Member States 
(14).
To ensure clear classifi cation and increase the 
reliability of these recommendations, cooperation is 
essential between a coordination group and EMA. 
In line with this, the Regulation stipulates that these 
recommendations should be made public once 
information of commercial importance is removed 
(14).
Grouping of variations
In addition to the standard application for each 
variation, the Regulation allows for submission of 
a single application or notifi cation for a group of 
variations to facilitate assessment of variations and 
reduce the administrative burden. Earlier, it was 
possible to report multiple variations together only 
if one variation led to other or multiple variations 
(15, 16).
Extensions of marketing authorisations
The Regulation lays down a list of variations 
considered to be extensions of marketing authorisations 
such as new doses or new pharmaceutical forms. 
Variations in this category are evaluated in the same 
procedure as the initial marketing authorisation, as 
they could lead to a new authorisation or amendment 
of the existing authorisation (14). The fi nal decision is 
left to the Member State and the same variation could 
result in a new authorisation in one Member State or 
in an amendment in another.
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Procedures (including worksharing)
The Regulation defi nes procedures for accepting 
variations to marketing authorisations granted 
pursuant to decentralised (Table 3) and centralised 
(Table 4) procedures. Each is divided according to 
the type of variation. The Regulation also defi nes 
the deadlines for implementation of each variation 
following approval (14).
If a variation leads to a change in the summary of 
product characteristics, package leafl et, or product 
labelling, these are to be revised with an assessment 
of the variation. Procedures concerning changes to 
an active substance for the purpose of the annual 
update of a human influenza vaccine, which are 
considered type II variations, are the same as for other 
medicinal products, though with shorter deadlines. 
The Regulation also defi nes the deadlines for the 
submission and assessment of clinical information and 
information on the stability of the vaccine (14). 
Worksharing procedure is special procedure set 
by the Regulation, that involve a reference authority, 
selected among the competent authorities of the EU 
Member States or EMA, which approves variations 
on behalf of all involved authorities. This applies to 
minor type IB variations, major type II variations or a 
group of variations that does not include extension of 
marketing authorisation and which relates to several 
marketing authorisations of the same holder. The 
reference authority can be EMA if at least one of the 
authorisations was granted pursuant to the centralised 
procedure, or a competent authority of a Member State 
selected by the coordination group (14). Procedures 
depending on the type of variation are described in 
Table 5. Worksharing procedure is intended to avoid 
duplication of work and to make possible simultaneous 
implementation of the same variation(s) in several 
Member States.
LEGAL DISCREPANCIES BETWEEN THE 
EU AND CROATIA
Croatian Medicinal Products Act and two 
related ordinances were passed before the European 
Commission Regulation No. 1234/2008 came into 
effect, and there are evident differences between them. 
The greatest difference is in categorisation of variations 
and procedures for their approval. The Croatian 
legislation does not defi ne “groups of variations” 
and “extensions of marketing authorisation” in the 
manner defined by the EC Regulation. Croatian 
legislation does not allow implementation of any 
type of variation before its approval. In addition, 
minor type IB variations do not include unforeseen 
variations; instead they are clearly listed in the 
Ordinance on the procedure and method of granting 
marketing authorisations for medicinal products (6). 
Major type II variations however include variations 
not considered minor. Croatian legislation also has not 
yet included the worksharing procedure established 
by the new EC Regulation. Variations to medicinal 
products approved in the EU, and which have been 
approved and are present on the Croatian market 
will be reported pursuant to the Ordinance on special 
conditions for placing medicinal products authorized 
in the Member States of the European Union on the 
market of the Republic of Croatia (7). This Ordinance 
distinguishes only minor types IA and IB variations, 
major type II variations, and variations due to urgent 
safety restrictions. With time these differences may 
hinder the implementation and approval of variations 
as defi ned by the current Croatian regulations.
To maintain the efficiency of the Croatian 
regulatory system, the fastest solution would be to 
amend the Ordinance on special conditions (7) to 
conform to the EC Regulation 1234/2008.
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Table 4 Procedures and deadlines for approval of variations of medicinal products through centralised procedure (CP)
CP/ minor 




submits notifi cation 
and documents 
to the European 
Medicines Agency 
within 12 months 
of implementation 








holder and European 
Commission within 30 
days of its decision on 
the variation and on 
possible amendments 





type IB (when 




submits notifi cation 





receipt of the valid 
notifi cation
If the European 
Medicines Agency 
does not deliver an 
unfavourable opinion 
to the marketing 
authorisation holder 
within 30 days of 
acknowledgement of 
receipt, the notifi cation is 
accepted
European Medicines 
Agency informs the 
marketing authorisation 
holder and European 
Commission of acceptance 
of the notifi cation and of 
possible amendments to 




type IB (when 
the variation is 
rejected)
European Medicines 
Agency informs the 
marketing authorisation 




holder may submit an 
amended notifi cation 
to European Medicines 
Agency within 30 
days of receipt of the 
unfavourable opinion, 
which will be assessed 
and the fi nal opinion 
delivered to the 
marketing authorisation 
holder and European 
Commission within 30 
days
If the marketing 
authorisation holder does 
not amend the notifi cation 
as required, it shall be 
considered rejected, and 
the European Medicines 
Agency shall inform the 
marketing authorisation 
holder and European 







for approval of 
the variations and 





receipt of the valid 
application
European Medicines 
Agency issues its opinion 
on the valid application 
within 60 days of receipt 
(may be reduced in 
urgent situations or 
extended to 90 days 
for amendments to 
therapeutic indications)
The European Medicines 
Agency may request 
supplementary information 
from the marketing 
authorisation holder. The 
procedure is suspended 




for Human Use 
of the European 
Medicines 
Agency issues its 
opinion on the 
application, in line 
with Commission 
Regulation EC No 
726/2004
European Medicines 
Agency informs the 
marketing authorisation 
holder and European 
Commission of the fi nal 
opinion within 15 days
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Sažetak
NOVA UREDBA EUROPSKE KOMISIJE O IZMJENAMA – UČINAK NA HRVATSKO 
ZAKONODAVSTVO
Uvođenje izmjena u dokumentaciju o lijeku na temelju koje je lijek dobio odobrenje za stavljanje u promet 
mora biti provedeno na način da te izmjene ne utječu na kakvoću, djelotvornost i sigurnost primjene 
lijeka. Navedeno je u Republici Hrvatskoj regulirano Zakonom o lijekovima i pratećim Pravilnicima koji 
su uvelike harmonizirani s propisima Europske unije. Hrvatski propisi u zadnjih 12 godina doživjeli su 
niz promjena u cilju donošenja potpunijih i jasnijih odredbi. Paralelno i u Europskoj uniji nastojalo se je 
pojednostaviti rješavanje izmjena te je donesena nova Uredba o izmjenama.
Nova Uredba EK o izmjenama donesena je nakon stupanja na snagu važećih hrvatskih propisa s područja 
lijekova i njihovom usporedbom uočavaju se razlike u defi niranju i pristupu rješavanja određenih vrsta 
izmjena u Hrvatskoj i zemljama EU.
Moglo bi se dogoditi da će navedene razlike, otežati provođenje procedura o odobravanju izmjena na način 
kako defi niraju hrvatski propisi. Jedan od načina kako bi se mogla zadržati jednaka efi kasnost hrvatskog 
regulatornog sustava jest pristupiti izmjeni Pravilnika o posebnim uvjetima za stavljanje gotovog lijeka u 
promet u Republici Hrvatskoj koji ima odobrenje u Europskoj uniji.
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